Houston biotech start-up files for IPO

Kiromic Biopharma has filed for an Initial Public Offering (IPO). It plans to raise $20 million. The company is based in the Medical Center district. It was formed in 2006, though it had minimal operations until 2012.

The company is developing immunotherapies for blood cancers and solid tumors. It will use artificial intelligence and its proprietary neural network platform to identify new surface tumor targets. These targets can then be used to create therapies such as antibody therapies, T cell therapies and vaccine therapies. The company has three early-stage product candidates.

The CEO is Maurizio Chiriva Internati. He has been in that role since February 2018, though he joined the company in 2012. He has been an Associate Professor at MD Andersen Cancer Center since August 2019.

Tony Tontat is the CFO and COO. He joined the company, initially as a consultant, in April 2018. He has helped raise funds for biotech public companies such as Sorrento Therapeutics and NantKwest.

The company plans to list on the NYSE American under the symbol ‘KRBP’. No pricing terms were disclosed.

SEC filing – Kiromic Biopharma S-1



Sign up for my newsletter

Leave a Reply

Your email address will not be published. Required fields are marked *